Sage Therapeutics Sponsor Briefing Document: Brexanolone Injection, For Intravenous Use, Presented To The Joint Meeting Of The FDA Psychopharmacologic Drug Advisory Committee & Drug Safety & Risk Management Advisory Committee

This briefing contains information that was presented by Sage Therapeutics (Sage) to the Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA on November 2, 2018. The information is in regards to Sage's brexanolone injection for intravenous use, a novel product developed by Sage for the treatment of postpartum depression . . .